Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer

By Tecimer C.   Doering D.L.   Goldsmith L.J.   Meyer J.S.   Abdulhay G.   Wittliff J.L.  

Gynecologic Oncology, Vol. 80, Iss. 1, 2001-01 ,pp. : 48-55

Elsevier

Access to resources Recommend Favorite

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer

By Fredstorp-Lidebring M.   Bendahl P.-O.   Brunner N.   Casslen B.   Hogberg T.   Langstrom-Einarsson E.   Willen R.   Ferno M.  

European Journal of Cancer, Vol. 37, Iss. 18, 2001-12 ,pp. : 2339-2348

Elsevier

Access to resources Recommend Favorite

Differential mRNA Expression of Urokinase-Type Plasminogen Activator, Plasminogen Activator Receptor and Plasminogen Activator Inhibitor Type-2 in Normal Human Endometria and Endometrial Carcinomas

By Foca C.   Moses E.K.   Quinn M.A.   Rice G.E.  

Gynecologic Oncology, Vol. 79, Iss. 2, 2000-11 ,pp. : 244-250

Elsevier

Access to resources Recommend Favorite

Expression and prognostic value of plasminogen activator inhibitor type 1 in node-negative breast cancer

By Wang Bin  

The Chinese-German Journal of Clinical Oncology, Vol. 7, Iss. 6, 2008-06 ,pp. : 339-343

Springer Publishing Company

Access to resources Recommend Favorite